Paraptosis: a non-classical paradigm of cell death for cancer therapy

• Published in: Acta pharmacologica Sinica Vol. 45; no. 2; pp. 223 - 237
• Main Authors: Xu, Chun-cao, Lin, Yi-fan, Huang, Mu-yang, Zhang, Xiao-lei, Wang, Pei, Huang, Ming-qing, Lu, Jin-jian
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.02.2024
• Subjects: Biomedical and Life Sciences; Biomedicine; Immunology; Internal Medicine; Medical Microbiology; Pharmacology/Toxicology; Review Article; Vaccine; ER stress; cancer therapy; paraptosis; mitochondria; endoplasmic reticulum
• ISSN: 1671-4083; 1745-7254
• DOI: 10.1038/s41401-023-01159-7

Due to the sustained proliferative potential of cancer cells, inducing cell death is a potential strategy for cancer therapy. Paraptosis is a mode of cell death characterized by endoplasmic reticulum (ER) and/or mitochondrial swelling and cytoplasmic vacuolization, which is less investigated. Considerable evidence shows that paraptosis can be triggered by various chemical compounds, particularly in cancer cells, thus highlighting the potential application of this non-classical mode of cell death in cancer therapy. Despite these findings, there remain significant gaps in our understanding of the role of paraptosis in cancer. In this review, we summarize the current knowledge on chemical compound-induced paraptosis. The ER and mitochondria are the two major responding organelles in chemical compound-induced paraptosis, which can be triggered by the reduction of protein degradation, disruption of sulfhydryl homeostasis, overload of mitochondrial Ca 2+ , and increased generation of reactive oxygen species. We also discuss the stumbling blocks to the development of this field and the direction for further research. The rational use of paraptosis might help us develop a new paradigm for cancer therapy.